Skip to main content Back to Top

Accelerating Biosimilar Adoption: Conversation with the Experts

Broadcast Date: August 19, 2022


Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Learn from experts in the field as they discuss barriers and key strategies for biosimilar adoption.


Russell D. CohenRussell D. Cohen, MD, FACG, AGAF is Professor of Medicine and Medical Director for offsite operations in the Department of Medicine, Section of Gastroenterology at the University of Chicago in Illinois. In addition, he is Director of the Inflammatory Bowel Disease Center and the Co-Director of the Advanced IBD Fellowship Program at the University of Chicago. Dr. Cohen earned his BS in biological sciences at Cornell University in Ithaca, New York, and his MD with honors at Mount Sinai School of Medicine in New York City. He completed his Residency in Internal Medicine at Harvard's Beth Israel Hospital, and his GI Fellowship and IBD Senior Fellowship at the University of Chicago. He has been Principal Investigator and Co-investigator for more than 185 research projects in his field, has edited three medical text books, and has authored or coauthored more than 200 articles, abstracts, reviews, books, book chapters, and audiotapes primarily devoted to Crohn's disease and ulcerative colitis.

Laura PolonskyLaura Polonsky, PharmD, BCPS, is a System-wide Clinical Coordinator for Formulary and Pharmacy Clinical Programs at Sutter Health, a not-for-profit integrated healthcare delivery system headquartered in Sacramento, California of 24 acute care hospitals and over 200 clinics. Dr. Polonsky received her PharmD degree from University of the Pacific – School of Pharmacy and completed a Clinical Pharmacy Practice Residency at UCSF Medical Center in San Francisco, California. Currently, among her various Sutter Health system-wide responsibilities, Dr. Polonsky coordinates the work of the Biosimilar Subcommittee of Sutter Health System Pharmacy and Therapeutics Committee.

Lisa SivellLisa Sivell, PharmD, is Director of Medical Benefit Drug Management at Blue Cross Blue Shield of Michigan where she is responsible for clinical and medical policies, operational process developments, and improvements in pharmacy with a focus on medical benefit medications. Through innovation and strategy development, Lisa and her team have implementation various programs resulting in improved member health outcomes and cost savings. Programs such as Site of Care, Biosimilar Strategy, and Waste Management programs have driven results for Blue Cross customers and members.

Barbara B. NussbaumBarbara B. Nussbaum, BS Pharm, PhD, joined the ASHP Foundation as the Vice President for Research and Education in 2015 after four years with the ASHP Office of Program Development as Director, Adult Learning and Educational Programs. Her role at the Foundation is to provide strategic direction for the creation and administration of high-impact programs in the areas of research and leadership recognition and development. Barbara received her pharmacy degree from the University of Maryland at Baltimore and doctoral degree from Virginia Tech in Adult Learning and Human Resources Development.


Relevant Financial Relationship Disclosures

The following persons in control of this activity’s content have relevant financial relationships: Russel D. Cohen:

  • Speakers bureau: Pfizer, AbbVie, Takeda
  • Scientific Advisory Board: AbbVie, Bristol-Myer Squibb/Celgene, Genentech, Gilead, Hoffman LaRoche, Janssen, Lilly, Pfizer, Takeda, UCB
  • Research Grants: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb/Celgene, Genentech, Gilead, Hollister, MedImmune, Mesoblast, Osiris, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres, Takeda, UCB

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As defined by the Standards of Integrity and Independence definition of ineligible company. All relevant financial relationships have been mitigated prior to the activity.   


The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Provided by ASHP
Sponsored by Amgen